---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-25-000077"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:56:47.886537+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports interim Phase 2a data: 39% ORR, 81% DCR in first-line pancreatic cancer

## Summary
- As of May 26, 2025 cutoff: 1 CR, 13 PR (4 pending confirmation), 15 SD among 36 evaluable patients; DCR 81%, ORR 39%.
- In 320 mg ITT population (n=34): 94% OS and 72% PFS at 6 months median follow-up; median OS and PFS not reached.
- Grade≥3 TEAEs in ≥10% of 320 mg patients: anemia (18%) and neutropenia (15%); no Grade 5 events.
- Additional data expected Q4 2025; pivotal trial of atebimetinib+mGnP in 1L pancreatic cancer planned for 2026, pending regulatory feedback Q4 2025.

## SEC filing metadata
- accession: 0001790340-25-000077
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000077/0001790340-25-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000077/imrx-20250617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-25-000077
- JSON: https://secwatch.observer/filing/0001790340-25-000077.json
- Plain text: https://secwatch.observer/filing/0001790340-25-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.